RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine shown to provide partial protection against malaria in young children. The vaccine will be provided to young children through national immunization programs in parts of three sub-Saharan African countries beginning in 2019.
RTS,S received a positive scientific opinion from the European Medicines Agency in 2015 and was recommended by the World Health Organization (WHO) for a pilot implementation program to assess the feasibility of administering the required four doses of the vaccine in children, the vaccine’s role in reducing childhood deaths and severe malaria, and its safety in the context of routine use. The country-led and WHO-coordinated Malaria Vaccine Implementation Programme will also provide data and information for a WHO policy recommendation on the broader use of the vaccine.
RTS,S was created in 1987 by scientists working in GSK laboratories. In early 2001, GSK and PATH—with the support of the Bill & Melinda Gates Foundation—entered into a partnership to develop the vaccine for infants and young children living in malaria endemic regions in sub-Saharan Africa. Its efficacy was established in a Phase 3 trial that concluded in 2014.
RTS,S aims to trigger the immune system to defend against the first stages of malaria when the Plasmodium falciparum parasite enters the human host’s bloodstream through a mosquito bite and infects liver cells. The vaccine is designed to prevent the parasite from infecting the liver, where it can mature, multiply, reenter the bloodstream, and infect red blood cells, which can lead to disease symptoms. To learn more about RTS,S, read the fact sheet.